<DOC>
	<DOCNO>NCT01129336</DOCNO>
	<brief_summary>This study evaluate zoledronic acid 's anti-cancer effect Circulating Tumor Cell ( CTCs ) measurements patient HER2-negative metastatic breast cancer without bone metastasis .</brief_summary>
	<brief_title>Effect Zoledronic Acid Anti-Cancer Treatment Metastatic Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Written inform consent Female patient ( age ≥18 year ) HER2negative metastatic breast cancer ( stage IV ) Patients receive chemotherapy hormonal therapy Patients bone metastasis ≤1 prior treatment metastatic breast cancer . Patients newly diagnose metastatic breast cancer may receive adjuvant neoadjuvant chemotherapy long treatment complete ≥12 month prior relapse . Asymptomatic brain metastasis permit follow criterion meet : 1. sign clinical progression know progression brain metastasis 2. steroid least 2 week prior study enrollment Stable renal function : two serum creatinine determination &lt; 3 mg/dL , obtain less 7 day apart ( one value may obtain within 6 week prior Screening ; second must obtain Screening ) ECOG performance status 0 1 Life expectancy ≥ 6 month Negative serum pregnancy test Ability willingness comply study requirement Known hypersensitivity zoledronic acid bisphosphonates Patients history another malignancy within last two year prior study enrollment , except cure basal cell carcinoma skin excise carcinoma site cervix Use concurrent investigational agent prohibit . Prior use investigational agent permit discontinue ≥30 day prior Screening . No prior therapy antiresorptive agent Patients active brain metastasis meningeal metastasis Current recent ( six month prior initial study drug treatment ) severe cardiovascular disease ( define uncontrolled congestive heart failure ) , hypertension refractory treatment , poorly control Type I/II diabetes mellitus Current active dental problem include dental abscess infection jawbone ( maxilla mandible ) current prior diagnosis osteonecrosis jaw Patients receive radiotherapy ≤ 4 week prior study enrollment recover radiotherapyrelated toxicity . Palliative radiotherapy bone lesion ≤ 2 week prior study enrollment allow Patients undergone major surgery ( e.g. , intrathoracic , intraabdominal intrapelvic ) ≤ 4 week prior study enrollment recover side effect therapy Diminished renal capacity : calculated creatinine clearance ( CrCl ) &lt; 30 mL/min ( base CockcroftGault formula ) Corrected ( i.e. , adjust serum albumin ) serum calcium &lt; 8.0 mg/dL ( 2.00 mmol/L ) ≥ 12 mg/dL ( 3.00 mmol/L ) Pregnant breastfeed female Women childbearing potential willing/able use effective method birth control ( e.g. , abstinence , oral contraceptive implant , IUD , vaginal diaphragm sponge , condom spermicide ) History noncompliance medical regimen and/or patient consider unreliable History bone metabolism disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>HER2-negative</keyword>
	<keyword>HER2</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>First Line breast cancer</keyword>
	<keyword>Second Line breast cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Stage IV breast cancer</keyword>
	<keyword>Progression free survival</keyword>
	<keyword>PFS</keyword>
	<keyword>Circulating Tumor Cells</keyword>
	<keyword>CTCs</keyword>
	<keyword>Zoledronic acid</keyword>
	<keyword>HER2-negative metastatic breast cancer patient without bone metastasis</keyword>
</DOC>